Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27393353 | 0.85 | MEN1 (0.42) | MEN1KMT2ARAB9ANPC1POLB | |
| SCHEMBL31716524 | 0.85 | MEN1 (0.42) | MEN1KMT2ARAB9ANPC1POLB | |
| SCHEMBL6697591 | 0.83 | MEN1 (0.45) | MEN1KMT2ARAB9ANPC1POLB | |
| SCHEMBL9517788 | 0.83 | MEN1 (0.41) | MEN1KMT2ARAB9ANPC1POLB | |
| SCHEMBL6697793 | 0.83 | ALDH1A1 (0.45) | MEN1KMT2ARAB9ANPC1POLB | |
| SCHEMBL9810566 | 0.82 | MEN1 (0.42) | MEN1KMT2ARAB9ANPC1POLB | |
| SCHEMBL32688719 | 0.81 | MEN1 (0.41) | MEN1KMT2ARAB9ANPC1POLB | |
| SCHEMBL6697213 | 0.80 | LMNA (0.42) | MEN1KMT2ARAB9ANPC1POLB | |
| SCHEMBL6694096 | 0.80 | ALDH1A1 (0.40) | MEN1KMT2ARAB9ANPC1POLB | |
| SCHEMBL13121506 | 0.80 | MEN1 (0.40) | MEN1KMT2ARAB9ANPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2697217-B1 | GLYCOSIDE DERIVATIVES AND THEIR USES FOR THE TREATMENT OF DIABETES | NOVARTIS AG (CH) | 2016-12-28 | — | — | EP | claimed |
| EP-2697217-A1 | GLYCOSIDE DERIVATIVES AND THEIR USES FOR THE TREATMENT OF DIABETES | Novartis AG (CH) | 2014-02-19 | — | — | EP | claimed |
| US-8614195-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2013-12-24 | — | — | US | claimed |
| US-20130018005-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2013-01-17 | — | — | US | claimed |
| US-20120264700-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2012-10-18 | — | — | US | claimed |
| WO-2012140597-A1 | GLYCOSIDE DERIVATIVES AND THEIR USES FOR THE TREATMENT OF DIABETES | NOVARTIS AG (CH) | 2012-10-18 | — | — | WO | claimed |
| EP-2697217-B1 | GLYCOSIDE DERIVATIVES AND THEIR USES FOR THE TREATMENT OF DIABETES | NOVARTIS AG (CH) | 2016-12-28 | — | — | EP | disclosed |
| EP-2697217-A1 | GLYCOSIDE DERIVATIVES AND THEIR USES FOR THE TREATMENT OF DIABETES | Novartis AG (CH) | 2014-02-19 | — | — | EP | disclosed |
| US-8614195-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2013-12-24 | — | — | US | disclosed |
| US-20130018005-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2013-01-17 | — | — | US | disclosed |
| WO-2012140597-A1 | GLYCOSIDE DERIVATIVES AND THEIR USES FOR THE TREATMENT OF DIABETES | NOVARTIS AG (CH) | 2012-10-18 | — | — | WO | disclosed |
| US-20120264700-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264700-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | SLC5A1, SLC5A2, UGT2B7 | MEN1 1200/4885KMT2A 4179/4885RAB9A 3046/4885 |
| US-20130018005-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | SLC5A1, SLC5A2, UGT2B7 | MEN1 1200/4885KMT2A 4179/4885RAB9A 3046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.